Formulation and evaluation of transdermal patches of papaverine hydrochloride
Main Article Content
Abstract
PVP, PVA: PVP and Eudragit RL-100: Eudragit RS-100 using different ratios. The physicochemical parameters such
as flexibility, thickness, smoothness, weight variation, moisture content, hardness and tensile strength were evaluated for
the prepared patches. The formulation exhibited flexibility, uniform thickness and weight, smoothness, good drug content
(92 to 96%), and little moisture content. The in vitro diffusion studies were carried out using modified Keshery-Chein cell
using cellophane as the diffusion membrane and the formulation followed the Higuchi diffusion mechanism. The formulation
containing PVA: PVP as polymers showed faster release rate (hydrophilic polymers) compared to Eudragit RL-100: Eudragit
RS-100 (hydrophobic polymers) or combination of hydrophilic and hydrophobic polymers (ethyl cellulose and PVP). The
stability studies indicated that all the patches maintained good physicochemical properties and drug content after storing
the patches in different storage conditions. Compatibility studies indicated that there was no interaction between the drug
and polymers. In vivo studies showed that papaverine hydrochloride helps in decreasing the effect of isoproterenol-induced myocardial necrosis. Hence, the aim of the present study was to prepare the sustained release formulation (Transdermal patches) of the drug using different blend of polymers. The formulated patches containing the hydroplilic polymers showed best release rate of drug.
Key words: Eudragit RL-100, eudragit RS-100, in vivo study, papaverine hydrochloride, transdermal patch
Downloads
Article Details
This is an Open Access article distributed under the terms of the Attribution-Noncommercial 4.0 International License [CC BY-NC 4.0], which requires that reusers give credit to the creator. It allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, for noncommercial purposes only.
References
Chein YW. Novel drug delivery systems. Vol. 50. New York: Marcel
Dekker, Inc.; 1992. p. 301.
Kanikannan N, Andega S, Burton S, Babu RJ, Singh M. Formulation and
in vitro evaluation of transdermal patches of melatonin. Drug Dev Ind
Pharm 2004;30:205-12.
Goodman and Gillman’s The Pharmacological Basis of Therapeutics. 10th
ed. New York: Medical Publishing Division; 2001. p. 448-9.
Gattani SG, Gaud RS, Chaturvedi SC. Formulation and evaluation
of transdermal films of chlorpheniramine maleate. Indian Drugs
;44:27-33.
Rao RP, Divan PV. Influence of casting solvent on permeability of
ethyl cellulose free films for transdermal use. East Pharma 1997;40:
-7.
Kusum DV, Saisivam S, Maria GR, Deepti PU. Design and evaluation
of matrix diffusion controlled transdermal patches of verapamil
hydrochloride. Drug Devel Indust Pharm 2003;29:495-503.
Kulkarni R, Doddayya H, Marihal SC, Patil CC, Habbu PV. Comparative
evaluation of polymeric films for transdermal application. East Pharma
;93:109-11.
Das MK, Bhattacharya A, Ghosal SK. Transdermal delivery of trazodone
hydrochloride from acrylic films prepared from aqueous latex. Indian
J Pharm Sci 2006;68:41-6.
Gannu R, Vishnu YV, Kishan V, Rao YM. development of nitrendipine
transdermal patches: In vitro and ex vivo characterization. Curr Drug
Deliv 2007;4:69-76.
Pandit V, Khanum A, Bhaskaran S, Banu V. Formulation and evaluation of
transdermal films for the treatment of overactive bladder. Int J Pharm
Tech Res 2009;1:799-804.
Sankar V, Johnson DB, Sivanad V, Ravichadran V, Raghuram S.
Design and evaluation of nifedipine transdermal patches. Indian
J Pharm Sci 2003;65:510-5.
Vogel GH, Vogel WH, editors. Drug discovery and evaluation:
Pharmacological assays New York: Springer Verlag Berlin Heidelburg;
p. 192.